Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors

Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have revolutionised the management of patients with high-grade serous and endometrioid ovarian cancer demonstrating significant improvements in progression-free survival. Whilst the greatest benefit is seen with BRCA1/2 mutant cancers,...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Rowan E, Elyashiv, Osnat, El-Shakankery, Karim H, Ledermann, Jonathan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547601/
https://www.ncbi.nlm.nih.gov/pubmed/36217436
http://dx.doi.org/10.2147/OTT.S272199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547601/
https://www.ncbi.nlm.nih.gov/pubmed/36217436
http://dx.doi.org/10.2147/OTT.S272199

Ejemplares similares